37.98
1.30 (3.54%)
| Previous Close | 36.68 |
| Open | 36.18 |
| Volume | 1,852,661 |
| Avg. Volume (3M) | 3,333,111 |
| Market Cap | 5,830,141,440 |
| Price / Book | 28.94 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Diluted EPS (TTM) | -1.97 |
| Total Debt/Equity (MRQ) | 7.80% |
| Current Ratio (MRQ) | 5.13 |
| Operating Cash Flow (TTM) | -221.77 M |
| Levered Free Cash Flow (TTM) | -125.17 M |
| Return on Assets (TTM) | -47.45% |
| Return on Equity (TTM) | -84.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Cogent Biosciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.04% |
| % Held by Institutions | 103.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deerfield Management Company, L.P. | 30 Sep 2025 | 9,053,118 |
| Fairmount Funds Management Llc | 30 Sep 2025 | 9,003,418 |
| Kynam Capital Management, Lp | 30 Sep 2025 | 7,886,172 |
| Commodore Capital Lp | 30 Sep 2025 | 7,250,000 |
| Tcg Crossover Management, Llc | 30 Sep 2025 | 6,798,162 |
| Vr Adviser, Llc | 30 Sep 2025 | 4,000,000 |
| Rtw Investments, Lp | 30 Sep 2025 | 3,467,486 |
| Janus Henderson Group Plc | 30 Sep 2025 | 3,178,043 |
| Paradigm Biocapital Advisors Lp | 30 Sep 2025 | 3,156,398 |
| Octagon Capital Advisors Lp | 30 Sep 2025 | 2,874,111 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 67.00 (JP Morgan, 76.41%) | Buy |
| Median | 52.00 (36.91%) | |
| Low | 34.00 (Baird, -10.48%) | Hold |
| Average | 51.60 (35.86%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 36.02 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 21 Jan 2026 | 55.00 (44.81%) | Buy | 39.90 |
| HC Wainwright & Co. | 06 Jan 2026 | 52.00 (36.91%) | Buy | 34.78 |
| 13 Nov 2025 | 50.00 (31.65%) | Buy | 33.83 | |
| JP Morgan | 19 Dec 2025 | 67.00 (76.41%) | Buy | 39.55 |
| Baird | 11 Nov 2025 | 34.00 (-10.48%) | Hold | 33.42 |
| Leerink Partners | 10 Nov 2025 | 50.00 (31.65%) | Buy | 32.46 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |